drugset / Trial / NCT06383780
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.
Timeline
- Start
- 2024-05-15
- Primary completion
- 2027-05-15
- Completion
- 2029-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Comparator | Tislelizumab | Monoclonal antibody | — | — |